menu ☰
menu ˟

FDA approves Lynparza, first treatment for BRCA-mutated breast cancer

13 Jan 2018
The FDA expanded the indication of olaparib to include patients with germline BRCA-mutated, HER-2-negative metastatic breast cancer who were previously treated with chemotherapy.Olaparib (Lynparza; AstraZeneca, Merck) — a poly ADP-ribose polymerase...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.